Catalyst Pharmaceuticals, Inc.

How big is Catalyst Pharmaceuticals, Inc.?

As of Jun 18, Catalyst Pharmaceuticals, Inc. has a market capitalization of $2.83 billion, with net sales of $534.64 million and a net profit of $197.35 million over the last four quarters.

Market Cap: As of Jun 18, Catalyst Pharmaceuticals, Inc. has a market capitalization of 2,832.26 million, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Catalyst Pharmaceuticals reported net sales of 534.64 million and a net profit of 197.35 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 727.63 million and total assets of 854.49 million.

What does Catalyst Pharmaceuticals, Inc. do?

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for rare diseases. As of March 2025, it reported net sales of $141 million and a net profit of $57 million, with a market cap of approximately $2.83 billion.

Overview: <BR>Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on developing and commercializing therapies for people with rare debilitating diseases within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 141 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 57 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 2,832.26 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 17.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.73 <BR>Return on Equity: 23.98% <BR>Price to Book: 3.57 <BR><BR>Contact Details: <BR>Address: 355 Alhambra Cir Ste 1250, CORAL GABLES FL: 33134-5038 <BR>Tel: 1 305 5292522 <BR>Website: https://catalystpharma.com/

Should I buy, sell or hold Catalyst Pharmaceuticals, Inc.?

Who are in the management team of Catalyst Pharmaceuticals, Inc.?

As of March 2022, the management team of Catalyst Pharmaceuticals, Inc. includes Patrick McEnany as Chairman, President, and CEO, with Charles O'Keeffe as Lead Independent Director and Richard Daly, Donald Denkhaus, and Dr. David Tierney as Independent Directors.

As of March 2022, the management team of Catalyst Pharmaceuticals, Inc. includes Mr. Patrick McEnany, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, Mr. Charles O'Keeffe holds the position of Lead Independent Director, while Mr. Richard Daly, Mr. Donald Denkhaus, and Dr. David Tierney serve as Independent Directors.

Is Catalyst Pharmaceuticals, Inc. overvalued or undervalued?

As of June 30, 2025, Catalyst Pharmaceuticals, Inc. is considered very attractive due to its undervalued status, evidenced by a P/E ratio of 17, a PEG ratio of 0.11, and a high ROCE of 108.10%, despite a recent year-to-date return of -2.25% compared to the S&P 500's 12.22%, while achieving a remarkable 507.14% return over the past five years.

As of 30 June 2025, the valuation grade for Catalyst Pharmaceuticals, Inc. has moved from attractive to very attractive, indicating a strong improvement in its valuation outlook. The company appears to be undervalued, supported by a P/E ratio of 17, a PEG ratio of 0.11, and an impressive ROCE of 108.10%. In comparison to peers, Catalyst's P/E ratio is significantly lower than Crinetics Pharmaceuticals, Inc. which has a P/E of -8.95, and much lower than Supernus Pharmaceuticals, Inc. with a P/E of 37.12, highlighting its relative attractiveness in the market.<BR><BR>Despite recent challenges, as evidenced by a year-to-date return of -2.25% compared to the S&P 500's 12.22%, Catalyst's long-term performance is noteworthy, with a remarkable 507.14% return over the past five years versus the S&P 500's 96.61%. This long-term outperformance, coupled with its strong valuation metrics, reinforces the view that Catalyst Pharmaceuticals is currently undervalued.

Is Catalyst Pharmaceuticals, Inc. technically bullish or bearish?

As of October 24, 2025, Catalyst Pharmaceuticals, Inc. shows a mildly bearish trend, with mixed signals from the MACD and daily moving averages, despite a bullish indication on the monthly Bollinger Bands.

As of 24 October 2025, the technical trend for Catalyst Pharmaceuticals, Inc. has changed from sideways to mildly bearish. The weekly MACD indicates a mildly bullish stance, but the monthly MACD is mildly bearish, suggesting mixed signals across different time frames. The daily moving averages also reflect a mildly bearish position. The Bollinger Bands show a bullish trend on the monthly chart, while the weekly chart remains sideways. Overall, the indicators suggest a mildly bearish sentiment, primarily driven by the daily moving averages and the monthly MACD. There is no available return data to compare the company's performance against the S&P 500.